Metabolic gene mesenchymal signatures and uses thereof
View Patent ↗Aspects of the invention relate to methods and compositions for characterizing or modulating the expression of metabolic mesenchymal genes. In some embodiments, methods for assessing the expression of metabolic mesenchymal genes and related gene signatures are provided that are useful for cancer classification, prognosis, diagnosis, or treatment selection.
1. A method for inhibiting or reversing an epithelial to mesenchymal transition in a cell of epithelial origin, the method comprising:
inhibiting expression in the cell of the metabolic mesenchymal gene DPYD, thereby inhibiting or reversing an epithelial to mesenchymal transition in the cell, and wherein expression of the metabolic mesenchymal gene is inhibited in the absence of exposure of the cell to 5′fluorouracil.
2. The method of claim 1 , wherein inhibiting expression comprises accumulating in the cell an exogenous inhibitory RNA that inhibits the metabolic mesenchymal gene.
3. The method of claim 1 , wherein the cell of epithelial origin is a cancer cell.
4. The method of claim 1 , wherein the cell of epithelial origin is in vivo.
5. The method of claim 1 , wherein the cell of epithelial origin is in vitro.
6. The method of claim 1 further comprising determining the extent to which inhibition of the metabolic mesenchymal gene affects invasiveness, migration ability, and/or one or more metastatic characteristics of the cell of epithelial origin.
7. The method of claim 1 further comprising assaying activity of the metabolic mesenchymal gene in the cell of epithelial origin.
8. The method of claim 1 further comprising assaying alterations in the growth and/or survival of the cell of epithelial origin.
9. The method of claim 1 , wherein the cell is of breast epithelial origin and wherein the method further comprises assessing the extent to which the cell is capable of mammosphere formation.
10. The method of claim 1 further comprising evaluating one or more epithelial markers on the cell.
11. The method of claim 1 further comprising determining whether the cell acquires a CD44 low /CD24 high expression profile.
12. The method of claim 1 further comprising determining dihydrouracil (DHU) and/or uracil levels in the cell.
13. The method of claim 1 further comprising determining a molar ratio of dihydrouracil (DHU) to uracil in the cell.
14. The method of claim 1 , wherein the cell is a breast cancer cell.
15. The method of claim 14 , wherein the breast cancer cell is a basal subtype-B breast cancer cell.
16. The method of claim 1 , wherein the cell is a hepatocellular carcinoma (HCC) cancer cell.
17. The method of claim 16 , wherein the HCC cancer cell is of a high grade cancer.